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Pituitary adenylate cyclase activating polypeptide (PACAP) is associated with
Alzheimer’s disease (AD), but its age-related effects are unknown. We chose the
rhesus macaque due to its closeness to human anatomy and physiology. We
examined four variables: aging, cognitive performance, amyloid plaques and PACAP.
Delayed nonmatching-to-sample recognition memory scores declined with age and
correlated with PACAP levels in the striatum, parietal and temporal lobes. Because
amyloid plaques were the only AD pathology in the old rhesus macaque, we further
studied human amyloid precursor protein (hAPP) transgenic mice. Aging was associated
with decreased performance in the Morris Water Maze (MWM). In wild type (WT)
C57BL/6 mice, the performance was decreased at age 24–26 month whereas in
hAPP transgenic mice, it was decreased as early as 9–12 month. Neuritic plaques in
adult hAPP mice clustered in hippocampus and adjacent cortical regions, but did not
propagate further into the frontal cortex. Cerebral PACAP protein levels were reduced
in hAPP mice compared to age-matched WT mice, but the genetic predisposition
dominated cognitive decline. Taken together, these data suggest an association among
PACAP levels, aging, cognitive function and amyloid load in nonhuman primates, with
both similarities and differences from human AD brains. Our results suggest caution in
choosing animal models and in extrapolating data to human AD studies.
Keywords: Alzheimer’s disease, PACAP, aging, nonhuman primates
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INTRODUCTION
Alzheimer’s disease (AD) is definitively diagnosed by the
presence of amyloid plaques, neurofibrillary tangles (NFT) and
functional impairment in multiple cognitive domains (Vinters,
2015). Our recent studies report a deficit in the levels of
pituitary adenylate cyclase activating polypeptide (PACAP) in
human AD brains, suggesting that intrinsic protective factors
are involved in AD pathogenesis (Han et al., 2014a,b). The
role of PACAP in cellular metabolic function is supported by
observations that PACAP protects mitochondrial function in the
presence of β-amyloid toxicity (Han et al., 2014b). Consistently,
the reduction of PACAP in human AD correlates with both
cognitive decline and severity of pathologic markers (Han et al.,
2015). A key question is whether aging, as an independent
factor reduces PACAP and thus at least partially enhances the
vulnerability to AD. Furthermore, is it possible that the reduction
of PACAP accelerates aging-associated dysfunction and enters a
vicious deteriorating cycle? Previous studies appear to support
this vicious cycle hypothesis indirectly. For example, PACAP
knockout mice show accelerated retinal aging (Kovács-Valasek
et al., 2017). PACAP transportation across the blood brain
barrier is reduced in aged mice (Nonaka et al., 2002). Vasoactive
intestinal peptide and pituitary adenylate cyclase-activating
polypeptide receptor type 1 (VPAC1) is downregulated in
multiple regions of aged rat brain (Joo et al., 2005; Lee et al.,
2010), suggesting that aging brain is less sensitive to PACAP
signaling. On the contrary, PACAP immunoreactive cells appear
to be paradoxically high in the aged gerbil hippocampus
except mossy fiber zone (Du et al., 2011). However, the
mutual interaction of aging factor and PACAP needs further
clarification.
Nonhuman primates are evolutionarily close to humans,
and like other mammals, do not spontaneously show the full
spectrum of neuropathological features characteristic of human
AD. On the other hand, macaques do show age-related memory
deficits (Rapp et al., 1997) that are reminiscent of those observed
in humans (Moffat and Resnick, 2002) and rodents (Barnes,
1979). Additionally, it has been reported that older monkeys can
show diffuse amyloid plaques, but rarely showmature NFT. Little
is known about what impact these neuropathological markers
may have on cognition in these animals.
A majority of transgenic animal models that are used
to study AD involve the human amyloid precursor protein
(hAPP) gene, which harbors one or more mutations found
in familial AD (Cavanaugh et al., 2014). In the J20 mouse
model, containing hAPP harboring multiple mutations, amyloid
plaques typically appear around 8–10 months of age (Mucke
et al., 2000). Preclinical tests of potential drug candidates in
this model are usually conducted before 6 months of age when
amyloid levels begin to increase, often because experiments that
maintain animals to older ages are costly to conduct. Pathologic
and cognitive features are less explored in these mice during
advanced age even though aging is the most paramount risk
factor associated with AD. An understanding of what makes an
aging brain more susceptible to such pathological conditions is
critical for the design of preclinical studies that aim to prevent or
delay disease progression (Franco and Cedazo-Minguez, 2014).
While an ideal model of AD is not available (Laurijssens et al.,
2013; Bilkei-Gorzo, 2014; Franco and Cedazo-Minguez, 2014),
further characterization of the brains of normal aging mice and
nonhuman primates, along with a mouse model of AD, allows us
to define aspects of brain aging that are expected to occur over the
lifespan and identify those that do or do not resemble the human
disease profile (Cavanaugh et al., 2014). In particular, it will be
highly informative to compare the same spectrum of pathologic,
biochemical and behavioral parameters among normal and
pathologic aging models from different species. This comparison
will point out key factors underlying common aging physiology
and pathology. Here we characterize cognitive performance and
PACAP protein in nonhuman primates ranging in age equivalent
to human ages from 24 years to 96 years. We further investigated
cognitive performance, amyloid plaques, and PACAP protein in
hAPP transgenic mice and compared to their wild type (WT)
littermates that were in an age range equivalent to 40–80 human
years, within the age range of onset of both familial and sporadic
AD (Friedland et al., 1988). We aim to compare these key AD
features in the transgenic mice during aging, and to compare
them with that in human AD.
MATERIALS AND METHODS
Animals
Twenty-four rhesus macaques (Macaca mulatta) were included
in this study, 15 males and 9 females. These animals ranged
in age from 8 years to 32 years (Supplementary Table S1).
These ages can be multiplied by a factor of 3 to provide
an approximate comparison to human aging (Tigges et al.,
1988) of approximately 24–96 years. The animals were housed
in pairs and were provided with environmental enrichment,
including socialization in a large pen, behavioral testing and
regular fruits and vegetables. These monkeys were all born and
housed continuously at the California National Primate Research
Center in Davis, CA, USA and were part of a long term study
of the effects of aging on the primate temporal lobe. At the
end of the data collection for that experiment, animals were
euthanized with an overdose of sodium pentobarbital (60 mg/kg,
intravenously), and transcardially perfused with a solution of
4% paraformaldehyde in 0.01% phosphate-buffered saline (pH
7.4), followed by a mixture of 4% paraformaldehyde and 10%
sucrose. After perfusion, the brains were extracted and placed
into a solution of 4% paraformaldehyde and 30% sucrose for
further cryoprotection. The entire brain of each monkey was
serial sectioned coronally at 30 µm while frozen on a sliding
microtome. A one in four section series was Nissl stained so
that sections of interest in the frozen material could be more
easily identified from the archived brains for future studies,
such as the present one (Thome et al., 2016). All procedures
on rhesus macaques followed an Animal Care and Use protocol
approved by the IACUC at the University of California,
Davis, CA, USA.
The hAPP transgenic mice (B6.Cg-Tg (PDGFB-APPSwInd)
20 Lms/2Mmjax, stock number 006293/J20) were generated as
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described previously (Mucke et al., 2000). The breeding pair was
purchased fromThe Jackson Laboratory (Bar Harbor, ME, USA).
This strain harbors hAPP with Swedish (K670N/M671L) and the
Indiana (V717F) mutations. The C57BL/6WTmice were used as
littermate controls. The breeding pair was housed in the Barrow
Neurological Institute (BNI) vivarium and the offspring were
genotyped using the protocol supplied by the vendor. A total
of 87 mice (51 WT, 36 hAPP) were included in this study with
a total mortality of 12% during the experiments (WT mortality
8%, hAPP mortality 17%). Individual animals may be used for
measuring multiple parameters. The procedures in all hAPP
transgenic mice were consistent with NIH Animal Care and Use
guidelines and were approved by the Institute Animal Care and
Use Committee (IACUC) at University of California, Davis, CA,
USA and BNI.
Cognitive Test for Rhesus Macaques
The Delayed Nonmatching-to-Sample Task (DNMS) was
conducted in the Wisconsin General Testing Apparatus as
described previously (Shamy et al., 2006). The first component of
the task was to present the ‘‘sample object’’ in the middle of three
wells in front of the monkey. The monkey could displace this
object during this phase of the task to receive food reward. After
varying delays (increasing from 10 s to 15 s, 30 s, 60 s and 10min),
the monkey was given a choice of two objects that cover the outer
wells. One object was the sample object and the other was novel.
A correct response was to displace the novel object to receive food
reward (this is the nonmatching rule). The delay interval utilized
for the present analysis was 10 min because it was the longest
delay tested, and thus the most challenging for the older animals.
The behavior scores were calculated to represent the percentage
of correct responses at that delay interval. The interval between
cognitive testing and euthanasia typically ranged from 6 months
to 3 years.
Histopathological Assessment of Plaque
Density and Neuronal Expression of
PACAP in Rhesus Macaque Brains
Thirty micron free floating coronal sections were stained with
thioflavin S and enhanced silver methods for amyloid plaques
(Braak and Braak, 1991). In addition, Immunohistochemistry
(IHC) was done with an antibody directed against amino acid
residue 1–16 of beta amyloid (6E10, BioLegend, San Diego, CA,
USA). Amyloid plaque density was graded and staged at standard
sites in frontal, temporal, parietal and occipital cortices as well
as hippocampus and entorhinal cortex, based on the aggregate
impression from the 30 µm stained sections. Neuritic plaque
density scores were obtained by assigning values of none, sparse,
moderate and frequent, according to the published CERAD
templates (Mirra et al., 1991). Based on studies of human brain
(Han et al., 2014a, 2015), PACAP is notably expressed in the
hippocampus, temporal lobe, striatum, and parietal lobe. We
selected samples of these four areas for analysis using the Paxinos
Atlas, Plate 70. The slide was stained with primary antibodies
(rabbit-anti-PACAP, Santa Cruz Biotechnology, Dallas, TX,
USA; mouse-anti-NeuN, Millipore, Billerica, MA, USA), and
then washed and stained with secondary fluorescent antibodies.
Omission of primary antibody was performed as a negative
control and human brain tissue was used as a positive control.
Images were taken using a Zeiss LSM 510 confocal microscope.
The PACAP (green) channel gain was uniformly set at 450 and
the NeuN nuclear (red) channel gain was set at 500. In
each anatomic site, three representative images were taken at
equidistance in a linear dimension: one image represents central
area and two images represent paracentral areas. On each image,
10 or more NeuN positive neurons were randomly selected
and outlined as Region of Interest (ROI) for analysis. The
PACAP fluorescence intensity in the defined ROI was recorded
(>30 neuronal ROIs for each image) and averaged. All analyses
were conducted blinded to the animal’s identity, age, or other
relevant information.
Morris Water Maze (MWM) for Mice
MWM testing was performed according to the protocol by
Morris (Morris, 1984) and as previously carried out in our
lab (Yin et al., 2011). Briefly, MWM tank (diameter = 1.5 m)
was divided into four quadrants at equal distance to the outer
perimeter. The water temperature was maintained at 24◦C.
The water was made opaque by adding 300 g non-toxic white
tempera powder (Jack Richeson and Co. Inc., Kimberly, WI,
USA). Each mouse was allowed to swim for 120 s and the
time spent to reach the platform (escape latency) was recorded
in each trial during the training period (target-on training).
Each mouse had 16 training trials divided equally during a
4-days period. In each trial, mice that successfully located
the platform were allowed to stay on the platform for 10 s,
whereas those that failed to locate the platform within the
defined time frame were placed on the platform for 10 s by the
experimenter. A single probe trial was conducted by removing
the platform (target-off test) on the 5th day, in which all mice
started from the farthest point opposite to the original target
platform location and were allowed to swim for 120 s. We
used the EthoVision 3.1 tracking system (Noldus Information
Technology Inc., Leesburg, VA, USA) to record and analyze the
data.
Two-Object Novel Object Recognition
(NOR) for Mice
NOR task was conducted in an open field arena with two
different types of objects (Hammond et al., 2004; Ennaceur,
2010). Both objects were generally consistent in height and
volume, but different in shape and appearance. During
habituation, the animals were allowed to explore an empty
arena. Twenty-four hours after habituation, the animals were
exposed to the familiar arena with two identical objects
placed at an equal distance from the arena walls. The next
day, mice were allowed to explore the open field in the
presence of the familiar object and a novel object to test
their long-term memory. The time spent in exploring each
object was recorded. The discrimination index (DI) was
calculated as:
DI = Time exploring new object− Time exploring old object
Total object exploring time
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Amyloid Plaque Stain for Mice
Mice were deeply anesthetized with isoflurane and
transcardiacally perfused with 0.1 M phosphate-buffer saline
(PBS). Brains were harvested and dissected on an ice plate.
Left hemispheres were fixed with 10% formalin (Thermo
Scientific Inc. Waltham, MA, USA) at 4◦C for at least 72 h. Right
hemispheres were immediately frozen in liquid nitrogen and
stored in −80◦C for biochemical assays (see ‘‘PACAP Elisa in
Mice’’ Section). The formalin fixed left hemispheric brain tissues
were embedded in paraffin blocks, coronally sectioned at 6 µm
thickness (between Bregma±2.5 mm, Figure 2A), and mounted
on Silane-coated glass microscope slides (Sigma, St. Louis, MO,
USA). For staining amyloid plaques, slides were deparafinized in
xylene and ethanol in the following series of procedures: 100%
xylene for 5 min twice, xylene/ethanol mix (1:1) for 5 min, 100%
ethanol 5 min, 95% ethanol 5 min, 70% ethanol 5 min, 50%
ethanol 5 min, and water for 5 min twice. Then the slide was
incubated in filtered 1% aqueous thioflavin-S (Sigma-Aldrich,
St Louis, MO, USA) for 10 min at room temperature in a
light-proof box. After two washes in 80% ethanol for 5 min
followed by a wash in 95% ethanol for 5 min, the slides were
rinsed thoroughly in distilled water. The slides were then sealed
with coverslips and stored at 4◦C.
PACAP Elisa in Mice
Frozen mouse brain tissues obtained from the hippocampal
formation and adjacent cortices (area indicated in Figure 2A
inset) were homogenized in RIPA buffer supplemented with
a proteinase inhibitor cocktail (Sigma-Aldrich, St Louis, MO,
USA). Protein samples were quantified for PACAP using
a standard enzyme-linked immunoassay kit (MBS720617,
MyBiosource Inc., San Diego, CA, USA) according to the
manufacturer’s protocol. Briefly, protein samples and the
standard PACAP were loaded and incubated with a biotin-
labeled PACAP antibody at 37◦C for 60 min. The plate was
washed with the washing buffer 5 times, followed by incubation
with chromogen solution at 37◦C for 10 min. The reaction
was stopped by adding a stop solution. The final colorimetric
density was measured at a wavelength of 450 nm using an
INFINITE M200Pro plate reader (Tecan systems Inc., San
Jose, CA, USA). Meanwhile, the total protein quantity was
determined with a Pierce bicinchoninic acid protein assay kit
(catalog #23227, Thermo Scientific, Waltham, MA, USA). To
eliminate the confounding factor of potential neurodegeneration,
we normalized the PACAP level to the measured protein level in
brain tissues. Therefore, PACAP in cortical tissues was expressed
as nanograms per milligram of total protein.
Data Analysis and Statistics
Correlation coefficients were examined using a Spearman linear
model unless indicated otherwise. If the linear model did not fit
well, we further tested nonlinear models (exponential, sigmoid
and polynomial) and chose themodel that best fit the data points,
as judged by the largest r2 (goodness of fit). We use one way
ANOVA with post hoc Tukey tests to compare mean values of
multiple groups, or two-way ANOVA with post hoc Bonferroni
tests if two intrinsic factors (age and genetic background) are
involved. A p value less than 0.05 was considered to be statistically
significant.
RESULTS
We examined cognition, plaques and PACAP expression in
rhesus monkeys in the age range from 8 years to 32 years old.
This age range is equivalent to 24–96 years old in a human life
span. A rhesus monkey that is 20 years old is equivalent to a
60 year old human. Therefore we define those 20 years old or
less as the young group and those above 20 years as the old
group.
We tested DNMS performance at a long delay (10 min),
and it progressively decreased with increasing age (r = −0.670,
P = 0.0003, Figure 1A).
Plaques were evident in the temporal and inferior parietal
lobes in most of the old rhesus monkeys. Of the areas analyzed,
the temporal lobe had the highest plaque density. Furthermore,
DNMS performance inversely correlated with both temporal and
parietal lobe plaque density (Figure 1B: r = −0.609, p = 0.002;
Figure 1C: r = −0.547, p = 0.007). Of note, only two (both aged
28 years old) showed amyloid plaques in the hippocampus. There
was no evidence of NFT in the brain.
We further characterized neuronal expression of PACAP
using a double staining immunohistochemical approach
(Figure 2A). While this approach is not as quantitative as
ELISA, it provides a semi-quantitative assessment specific to
the neuronal population. Within the four regions we examined
(hippocampus, parietal lobe, striatum and temporal lobe),
neuronal expression of PACAP showed a biphasic pattern; it
increased with age in the young group and then declined with
age in the old group (Figure 2B).
In the old group (≥20 year-old), neuronal expression of
PACAP in all four regions were inversely correlated with
advanced age (20–32 years; Parietal: Figure 3A, r = −0.743,
p = 0.000028; Striatal: Figure 3C, r = −0.556, p = 0.0046;
Temporal: Figure 3E, r = −0.686, p = 0.00019; Hippocampal:
Figure 3G, r = −0.651, p = 0.00054). Furthermore, DNMS
performance in the older animals showed a positive correlation
with PACAP intensity. In parietal, striatal, and temporal lobes,
the higher the neuronal expression of PACAP was, the better
the performance on the DNMS test. This did not hold true for
hippocampal PACAP (Parietal: Figure 3B, r = 0.469, p = 0.020;
Striatal: Figure 3D, r = 0.545, p = 0.005; Temporal: Figure 3F,
r = 0.136, p = 0.001; Hippocampal: Figure 3H, r = −0.023,
p = 0.105).
Since amyloid plaques were the only AD like pathology
present in rhesus monkeys, we used hAPP mice for further
studies. Human APP mice are reported to show memory
deficits as early as 4–5 months (Wright et al., 2013) or
6–7 months (Palop et al., 2003), as measured by different maze
paradigms. We tested hAPP mice at age groups of 9–12 months,
13–16 months and 24–26 months. Given that the mean lifespan
of a B6 mouse is approximately 800 days (Goodrick, 1975;
equivalent to 26.7 months), the group of 24–26 months old mice
is approximately equivalent to 80 human years. The age group of
9–12months is equivalent to 40 human years; this is when clinical
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FIGURE 1 | Cognitive performance in a delayed nonmatching-to-sample
(DNMS) task across age in rhesus macaques. (A) DNMS performance
(percent correct at a 10 min delay) declined linearly throughout the lifespan
(Pearson R = −0.67, P < 0.001). (B) DNMS performance inversely correlated
with temporal lobe plaque density (CERAD plaque score). (C) DNMS inversely
correlated with parietal lobe plaque density.
symptoms of familial AD appear. The age group 13–16 months
is equivalent to 60 human years, when sporadic AD onset begins
to increase, and memory may decline in the normal aging human
population.
FIGURE 2 | Age-related changes in pituitary adenylate cyclase activating
polypeptide (PACAP) in different brain areas of rhesus macaques.
(A) Immunohistochemistry (IHC) of PACAP. Double staining of NeuN (red) and
DAPI (blue) depicted neurons. Immunostaining intensity of PACAP (green) was
assessed within the randomly selected 10 neurons in each visual field. At least
three visual fields were assessed for each slide and averaged to calculate IHC
intensity of PACAP for each individual animal. PACAP intensity from each
region (hippocampus, parietal lobe, striatum and temporal lobe) was plotted
against age. (B) Biphasic pattern of PACAP across the life span.
We performed the MWM tests on each group. Learning is
indicated by reduced path lengths as training progressed. All
age groups in WT mice showed successful learning (Figure 4A).
Based on two-way repeated ANOVA, the age factor contributed
to 17% of the total variation (F = 27.91, p< 0.0001), training days
contributed to 24% of the total variation (F = 26.48, p< 0.0001),
and there was no interaction between the training factor and
age factors. While learning improvement was evident in all
age groups, the oldest age group (24–26 months) performed
relatively poorly in the first 3 days compared to the youngest
group (9–12 months, post hoc Bonferroni test, p < 0.01 in
day1, p < 0.001 in day2 and p < 0.05 in day 3). In hAPP
mice, the age factor contributed to 5.8% of the total variation
(F = 3.812, p < 0.05), the training factor contributed to
8.9% of variation (F = 3.893, p < 0.05), and there was no
interaction between the two factors (F = 0.433, p = 0.85,
two way repeated ANOVA, Figure 4B). However, post hoc
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FIGURE 3 | Correlation of age, PACAP and DNMS performance in old rhesus macaques. (A,C,E,G) Regional IHC intensity of neuronal PACAP in the old group of
rhesus macaques (20–32 years). PACAP levels in all four regions (the hippocampus, parietal lobe, striatum and temporal lobe) declined with age progression.
(B,D,F,H) Higher levels of regional PACAP correlated with better performance on the DNMS task in the old group of monkeys in Parietal (B) Striatal (D) and Temporal
lobe (F) while no correlation was found in the hippocampus (H).
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analysis did not suggest significant learning improvement over
the 4 days training period in any age group (p > 0.05,
Figure 4B).
In the probe test in which the platform was removed, we
calculated the ratio of the swim path length within the target
quadrant and that in the opposite quadrant. The hAPP mice
have an average ratio of 0.09 ± 0.04 in the 9–12 months group
(n = 17), 0.13 ± 0.11 in the 13–16 months group (n = 8), and
0.04 ± 0.01 in the 24–26 months group (n = 5). The mean
ratio in WT mice was 0.29 ± 0.14 in the 9–12 months group
(n = 19), 0.05 ± 0.11 in the 13–16 months group (n = 16),
and 0.10 ± 0.02 in the 24–26 months group (n = 12). Neither
the age factor (F = 0.502, p = 0.608) nor the genetic factor
(F = 0.359, p = 0.551) contributed significantly to the total
variation; and there was no significant interaction between these
factors (F = 0.625, p = 0.538, two way ANOVA, Figure 4C). The
DI obtained from the NOR tests in hAPP mice did not differ
from that of WT except in the 24–26 months group (Figure 4D).
The hAPP mice have an average DI of 0.39 ± 0.28 in the
9–12 months group (n = 17), 0.35 ± 0.16 in the 13–16 months
group (n = 8), and −0.03 ± 0.18 in the 24–26 months group
(n = 5). The mean DI in WT mice was 0.37 ± 0.31 in the
9–12 months group (n = 19), 0.52 ± 0.24 in the 13–16 months
group (n = 16) and 0.28 ± 0.21 in the 24–26 months group
(n = 1 2). Neither the age (F = 0.486, p = 0.617) nor genetic
(F = 0.313, p = 0.578) factors made a significant contribution to
FIGURE 4 | Age and genetic effects on Morris Water Maze (MWM) and Novel Object Recognition (NOR) performance in human amyloid precursor protein (hAPP)
and wild type (WT) mice. (A,B) Path length to reach the platform was progressively reduced during the 4-days training course in WT (A) and hAPP (B) mice. Note the
reduction was less in hAPP (B) than that of WT (A) mice. (C) In the probe test, the ratio of path length in the target quadrant and the opposite quadrant were
compared in the three age groups in WT and hAPP mice. (D) The discrimination index (DI) in the NOR test was compared in the three age groups and in hAPP and
WT mice. For all experiments in (A–C), two-way ANOVA and post hoc Bonferroni tests were applied. ∗ Indicates p < 0.05, ∗∗ indicates p < 0.01, ∗∗∗ indicates
p < 0.001.
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the total variance, nor was there a significant interaction (two-
way ANOVA, interaction = 0.65% of total variation, P = 0.925).
One exception was that in the 24–26 months age only, NOR-DI
of hAPP mice was significantly lower than that of WT (p < 0.05,
T-test, Figure 4D).
Next, we examined neuritic plaques on the serial coronal
sections made from brains of WT and hAPP mice (Figure 5A).
At the age of 9-months and older, all hAPP mice showed
thioflavin-S positive plaques in the hippocampus. A majority
of them also showed thioflavin-S positive plaques in cortices
adjacent to the hippocampus (the same coronal section,
Figure 5A). However, no thioflavin-S positive plaques were
found in frontal cortex or any other locations beyond the coronal
sections covering the hippocampal region. Thus, the amyloid
plaque distribution in hAPP mice does not resemble the typical
pattern seen in human AD brain. Even in the oldest hAPP
mice (24–26 months), the plaques did not propagate throughout
the brain. In WT, no thioflavin-S positive plaques were seen
regardless of age. Plaques within both hippocampus and cortex
increased in numbers with age in hAPP mice (hippocampus:
r2 = 0.478, p< 0.0001; cortical: r2 = 0.545, p< 0.0001, Figure 5B).
The hippocampal and cortical plaque numbers correlated with
each other (r2 = 0.627, p < 0.001, Figure 5C), although in
each individual animal the cortical plaque numbers were far
less than were the hippocampal plaque numbers (Figures 5B,C).
NOR-DI did not correlate individually with hippocampal or
cortical plaque numbers (data not shown). This may not be
surprising because NOR performance is influenced by both
hippocampal and cortical lesions (Antunes and Biala, 2012).
Because both hippocampal and cortical regions contributed to
NOR performance, we multiplied these two independent factors
to get the product of hippocampal and cortical plaque numbers
([H] × [C]), and fit NOR-DI with this product. NOR-DI
inversely correlated with the product of hippocampal and cortical
plaques (r = −0.373, p = 0.042, Figure 5D). Because we did not
know whether there were unequal contributions from these two
factors, we systematically varied the relative weight as follows:
we modified the product as [H]n[C]1, where [H] denoted the
hippocampal plaque number, [C] denoted the cortical plaque
number, and n was a factor reflecting the relative contribution
of [H] vs. [C]. By varying n, we found that NOR-DI correlated
best with [H]n[C] when n is in the range of 1.2–1.4 (Figure 5E).
PACAP is reduced in brains of AD patients (Han et al.,
2015) and 18-month old 3×Tg AD mice (Han et al., 2014b), so
we measured cerebral PACAP levels in different age groups of
hAPP mice (Figure 5F). The tissue taken for PACAP assessment
was restricted to the hippocampus and adjacent cortices (the
right panel, Figure 5A). The average cerebral PACAP was
0.20 ± 0.031 ng per mg total protein in the 9–12 months group
(n = 9), 0.18 ± 0.023 in the 13–16 months group (n = 6), and
0.17 ± 0.009 in the 24–26 months group (n = 5). The mean
PACAP level in WT mice was 0.31 ± 0.03 in the 9–12 months
group (n = 18), 0.28± 0.031 in the 13–16 months group (n = 14),
and 0.32± 0.042 in the 24–26months group (n = 8). Analyzed by
two-way ANOVA, the age factor did not significantly contribute
to the variation (0.79% total variation, F = 0.283, p = 0.755), but
the genetic factor did (23% total variation, F = 16.56, p = 0.0002).
This suggests hAPP genetic mutation overshadows the age factor
and dictates the expression levels of PACAP. Thus, the age
factor does not account for varying levels of PACAP in WT
mice. However, the genetic factor (hAPP) significantly decreased
PACAP in each age group compared with the same ageWTmice
(p < 0.05 in each age group, two-way ANOVA with post hoc
Bonferroni tests, Figure 5F).
DISCUSSION
Recent longitudinal studies reconfirm that cognitive
performance declines as age increases in AD but also, to a lesser
degree, in individuals without AD pathological features (Monsell
et al., 2014; Jack et al., 2015). However, in a subpopulation
of normal cognitive individuals, amyloid plaques can be
evident, albeit less severe than that of Alzheimer’s patients.
Patients without amyloid plaques tend to have better cognitive
performance scores, although patients with amyloid plaques
do not necessarily have worse cognition (Kawas et al., 2015),
suggesting additional protective factors may sustain normal
cognition. Although the amyloid plaque number inversely
correlates with premortem cognition, NFT correlate better
(Nelson et al., 2012). Among the various candidate protective
factors, PACAP levels significantly correlate with cognitive
performance and inversely correlate with amyloid plaques (Han
et al., 2015).
The older rhesus macaques examined here did exhibit
amyloid plaques in the brain. Most areas, however, contained
very low plaque densities, whereas the temporal lobe had the
highest density. Advanced age is a significant predictor of
these deposits: the older monkeys in this cohort were more
likely to contain plaques (r = 0.577, p < 0.01). Therefore, the
aging primate model and the non-AD aging human show some
similarities, where sparse to moderate amyloid plaques are often
detected at autopsy and increased with age. In the cognitive
domain, DNMS performance progressively declines with the
aging process (20–32 years, equivalent to 60–96 human years).
Importantly, amyloid plaque density, although not as heavy as
observed in human AD, correlates with a decline in cognition, as
assessed by the DNMS task, although this effect is not separable
from the effect of aging alone. Similar to humans, neuronal
PACAP levels in the macaque also correlate with cognitive
function in the older monkeys. Because PACAP levels were
previously measured only in older human brains (>65 years),
the levels in young human brain is unknown, but may show a
rise during aging as is observed here in the monkey. It would
be interesting to determine whether a similar age-dependent
PACAP decline exists in healthy human populations as is
observed here in older rhesus macaques.
Rodent ADmodels are commonly used to authentically reflect
the primary features of the disease. We characterized these
features in hAPP mice that were in an age range equivalent
to the human age of 40–80 years. We show here that MWM
performance decreases with age in WT mice, while in hAPP
mice performance was equally poor in all age groups older
than 9 months, suggesting that by middle age this genotype
already has cognitive impairments. While these relationships are
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FIGURE 5 | Amyloid plaque numbers in hAPP mice and their relation to age, MWM and NOR performance. (A) The left panel shows a typical plaque in hAPP mice
(bar length = 20 µm). These plaques were restricted to the hippocampus and adjacent cortices. These areas were outlined by the blue lines in the middle (coronal
view) and right (surface view) panels. Only one hemisphere was marked but the plaques were expressed on both sides. (B) Plaque numbers in the hippocampus and
the cortex increased with age progression. Hippocampus: r2 = 0.48, p < 0.0001; cortex: r2 = 0.55, p < 0.0001. (C) The hippocampal and cortical plaque numbers
correlated with each other (r2 = 0.63, p < 0.001). (D) NOR-DI inversely correlated with the product of hippocampal and cortical plaque numbers ([H] × [C]), Pearson
r = −0.37, p = 0.042. (E) NOR-DI linearly correlated with n. While the linear correlation existed when n = 1 (E) the correlation remained valid (p < 0.05) when n was in
the range of 0.8–1.8. The correlation was the strongest when n was between 1.2 and 1.4. (F) Cerebral PACAP levels were measured in three age groups of hAPP
and WT mice. The cerebral tissues only included the hippocampus and the cortex around hippocampus (indicated as in the right panel of (A). Two-way ANOVA and
post hoc Bonferroni tests were applied. ∗ Indicates p < 0.05.
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similar to that in the familial AD population, unlike human
AD patients, amyloid plaques in hAPP mice are restricted
to the hippocampus and adjacent cortices. It is unclear why
amyloid plaques in mice do not form or propagate to multiple
regions, as the APP-driving PDGFB transcription factor is
widely expressed in neurons throughout the rodent brain.
Because of the temporal lobe distribution of plaques, the plaque
numbers were correlated with hippocampus-based behavioral
tasks such as the MWM. Although mice with extensive plaque
deposition showed impaired performance on the MWM, MWM
performance was not linearly correlated with amyloid plaque
deposition. Non-linear relationships have been observed in early
clinicopathologic study in human AD (Blessed et al., 1968),
but a more recent meta-analysis predicts a linear relationship
between the amyloid plaque number and cognitive performance
in humans (Nelson et al., 2012). Thus, the relationship between
plaque burden and cognition in the hAPP mice in the present
study differs from human AD observations. This implies that
potential protective factors may not be sufficient to retain
cognition in the face of the imposed genetic predisposition for
plaque formation in this model. The high dosage of amyloid
clusters that are localized in mouse hippocampus may be so
strong that it overpowers such protective factors. While PACAP
reduction in human AD inversely correlates with amyloid
plaques and cognitive decline, brain PACAP levels in mice did
not correlate with plaque numbers or water maze performance
(data not shown). The hAPP mouse model was designed to
model familial AD, but not sporadic AD. The reduced cerebral
PACAP in hAPPmice is driven by hAPP gene rather than the age
factor, thus it does not resemble human studies where cerebral
PACAP is closely correlated with both cognitive function and
pathologic markers (Han et al., 2015).
In conclusion, nonhuman primates show an age-related
cognitive decline that is closely associated with both plaque
accumulation and cerebral PACAP reduction. For hAPP mice,
however, genetic factors appear to dominate PACAP reduction
and cognitive decline. Our results highlight the importance of
choosing animal models that are optimized for obtaining answers
to a given experiment’s specific question, when searching for a
deeper understanding of the disease.
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